# Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial

> **NCT04678739** · PHASE3 · COMPLETED · sponsor: **M Abdur Rahim Medical College and Hospital** · enrollment: 205 (actual)

## Conditions studied

- Covid19
- Covid-19 ARDS

## Interventions

- **DRUG:** Remdesivir
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04678739
- **Lead sponsor:** M Abdur Rahim Medical College and Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-15
- **Primary completion:** 2021-01-30
- **Final completion:** 2021-02-10
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2021-04-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04678739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04678739, "Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT04678739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*